VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

24th October 2012 - New research

ODM-101 FOUND TO BE MORE EFFECTIVE THAN STALEVO

ODM-101, a new L-dopa product currently being developed by Orion for the treatment of Parkinson's disease, has successfully completed Phase II Proof of Concept trial. The key results indicate that ODM-101 was more effective than the reference product Stalevo in the treatment of advanced Parkinson's Disease.

Stalevo is a standard drug for advanced Parkinson's patients experiencing end-of-dose wearing-off symptoms associated with L-dopa therapy. Stalevo is an enhanced L-dopa treatment containing three active substances in one tablet : L-dopa and the enzyme inhibitors entacapone and carbidopa. For more information go to Stalevo. Orion do not detail in which way ODM-101 and Stalevo are chemically different.

The study included more than 100 patients in Europe. The Principal Investigator said "This phase II study demonstrated that ODM-101 has potential to be significantly more effective than Stalevo in the daily treatment of Parkinson's disease patients with response fluctuations. ODM-101 reduced time periods during the day when patients do not have adequate treatment response. These benefits were possible without an increase in troublesome involuntary movements (dyskinesia)." For more news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports

                                    

 

 
2006-2012  Viartis
 
2015-08-29 19:25:13
 
[email protected]